Innoviva (INVA) EPS (Weighted Average and Diluted) Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.45% |
| Sep 30, 2025 | 32.95% |
| Jun 30, 2025 | 2.22% |
| Mar 31, 2025 | -26.62% |
| Sep 30, 2024 | -43.90% |
| Jun 30, 2024 | -29.33% |
| Mar 31, 2024 | 8.21% |
| Sep 30, 2023 | 17.91% |
| Jun 30, 2023 | -47.26% |
| Mar 31, 2023 | 9.24% |
| Sep 30, 2022 | 67.88% |
| Jun 30, 2022 | -30.12% |
| Mar 31, 2022 | 5.92% |
| Sep 30, 2021 | 47.25% |
| Jun 30, 2021 | 47.25% |
| Mar 31, 2021 | 83.84% |
| Dec 31, 2020 | 65.05% |
| Sep 30, 2020 | 53.42% |
| Sep 30, 2018 | 24.38% |
| Jun 30, 2018 | 27.16% |
| Mar 31, 2018 | 21.91% |
| Sep 30, 2017 | 20.75% |
| Jun 30, 2017 | 22.10% |
| Mar 31, 2017 | -30.57% |
| Dec 31, 2016 | 19.99% |
| Sep 30, 2016 | 18.65% |
| Jun 30, 2016 | 19.33% |
| Mar 31, 2016 | 16.47% |
| Dec 31, 2015 | 16.54% |
| Sep 30, 2015 | 33.18% |